Navigation Links
PathAI and Bristol Myers Squibb find positive association of digital PD-L1 expression with outcomes in nivolumab-treated patients in an exploratory analysis
Date:6/28/2020

PathAI, a global provider of artificial intelligence (AI)-powered technology for use in pathology research, announced that the results of an exploratory analysis of digital scoring of PD-L1 expression to assess response in patients treated with Bristol Myers Squibb’s PD-1 inhibitor, nivolumab was presented as a poster #2017 at the 2020 American Association for Cancer Research (AACR) Annual Meeting. AACR was held June 22 to June 24.

The key finding of this study shows that PathAI’s digital quantification of PD-L1 expression in samples across multiple tumor types identified more patients that were PD-L1 positive, while maintaining the same response rate as the PD-L1 positive population identified using the manual PD-L1 analysis. This retrospective analysis of melanoma (MEL) and urothelial carcinoma (UC) clinical trial samples compared both the prevalence and response characteristics of the manual PD-L1 read-outs to the AI-derived quantifications. The analysis showed the digital analysis has higher sensitivity for PD-L1 expression and accurate detection of low-level PD-L1 expression in patients compared to manual reading. In three retrospective analyses, patients who were PD-L1 negative by manual assessment, were shown to have improved outcomes among nivolumab treated patients when identified as positive by digital analysis. In all cohorts, as previously reported, anti-tumor activity was observed regardless of PD-L1 status.

Training a classifier for PD-L1 expression in multiple tumor types

In this study, digital scoring was conducted by PathAI’s research platform using an algorithm trained on annotations collected from a network of board-certified pathologists. PathAI collected tens of thousands of examples to train a classifier that automatically evaluates PD-L1 expression on tissue stained using the Dako PD-L1 IHC 28-8 pharmDX assay. Once trained, the models were applied to two Bristol Myers Squibb sponsored melanoma clinical trial sets (CheckMate067 and CheckMate238), and one clinical trial of advanced UC (CheckMate275). The AI-derived PD-L1 quantification of these samples showed high correlation to manual PD-L1 expression scoring results.

Positive association of digital PD-L1 expression in multiple tumor types with outcomes in nivolumab-treated patient

The response of the PD-L1 positive patients to the nivolumab therapy regimens, was assessed using RECIST overall response criteria. Results suggest that despite showing increased prevalence of PD-L1 positivity across multiple cut-off points (PD-L1+ TC = 1% and = 5%) by the digital predictions, the response rates were indistinguishable between digital and manual methods. Additionally, patients identified by digital but not manual assessment showed improved clinical benefit compared with patients identified as TC PD-L1 negative by both manual and digital methods. PathAI’s research platform and PD-L1 algorithm are not for use in diagnostic procedures.

“This poster shows the potential of an AI-powered PD-L1 test to provide improved patient selection over traditional manual scoring. Such a finding could have important future consequences for cancer patients,” said PathAI co-founder and Chief Executive Officer Andy Beck, M.D., Ph.D.

About PathAI
PathAI is a leading provider of AI-powered research tools and services for pathology. PathAI’s research platform promises substantial improvements to the accuracy of diagnosis and the efficacy of treatment of diseases like cancer, leveraging modern approaches in machine and deep learning. Based in Boston, PathAI works with leading life sciences companies and researchers to advance precision medicine. To learn more, visit pathai.com.

Read the full story at https://www.prweb.com/releases/pathai_and_bristol_myers_squibb_find_positive_association_of_digital_pd_l1_expression_with_outcomes_in_nivolumab_treated_patients_in_an_exploratory_analysis/prweb17220807.htm.


'/>"/>
Source: PRWeb
Copyright©2020 Vocus, Inc.
All rights reserved


Related medicine news :

1. PathAI Announces Strategic Investment from LabCorp
2. Bristol Hospital Selects Rendina to Develop Downtown Ambulatory Care Center
3. Celebrity Hairstylist Jim Bristol, Launches Botanically Infused Ultimate Clean Luxury Shampoo and Conditioner Under His Brand, Spa Inspired, Sulfate and Paraben Free
4. RE/MAX Realtors Kris and Keith Myers Helping Save the Lives of Children
5. RE/MAX Realtors Kris and Keith Myers Raising Funds for Children’s Hospital of Los Angeles
6. Texas Flip n Move Star Myers Jackson Talks Luxury Home Marketing at 11 SpyGlass Hill
7. Medicaid Health Plans of America CEO, Jeff Myers Anchors i2i Population Health’s 2017 User Conference
8. Higgins & Corder, LLC Welcomes Consultant Kristi Goyer-Myers
9. The General Richard B. Myers Veterans Biomedical Technology Program Receives Bank of America Grant to Help Provide Veterans a Pathway to Employment
10. Fortress Ventures, Compass Real Estate and Thrive Senior Living Announces the Ground Breaking of an Innovative New Senior Living Community in Ft. Myers, Florida
11. Women's Excellence Welcomes Jennifer Myers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2020)... ... August 31, 2020 , ... ... 1,400 N95 face masks to medical first responders across the United States. Since ... donations of personal protective equipment (PPE) medical centers , hospitals , ...
(Date:8/31/2020)... ... ... The pandemic and topsy-turvy economic outlook continues to put financial strain on many of us, ... the fat from our monthly expenses and put more into savings, if possible. , “That’s ... a financial safety net in place in case something were to happen to you,” says ...
(Date:8/29/2020)... ... 29, 2020 , ... When professor and author Randy Pausch was diagnosed with ... would. Rather than become melancholic, however, he put together a final lecture in Carnegie ... Pausch took a negative situation and turned it into something that inspired millions of ...
(Date:8/28/2020)... ... ... Integrated Viral Protection (IVP Air) today announced that the True North ... Biodefense Indoor Air Protection System that is the first system designed and proven to ... with the filtration system on September 8th. , The IVP Air S1 model ...
(Date:8/27/2020)... ... 2020 , ... Evolution Labs announced today that Florida Virtual ... Suite360:Mental Health and Prevention, a program developed to help students navigate a range ... Florida schools and districts must provide their students with preventative lessons after recent ...
Breaking Medicine News(10 mins):
(Date:8/27/2020)... ... August 27, 2020 , ... Bleep LLC, maker of the DreamPort mask-less CPAP ... the company’s new spokesperson. , “In my line of work, a good night of ... Bleep DreamPort it was a Bleeping no brainer for me,” said Jensen. “From the ...
(Date:8/26/2020)... (PRWEB) , ... August 26, 2020 , ... AseptiScope, a ... Infection Control Company of the Year by MedTech Outlook. , “AseptiScope is ... “For the first time, clinicians who wear gloves on their hands, goggles on their ...
(Date:8/26/2020)... ... August 26, 2020 , ... Crossroads Hospice & Palliative ... and CPCO to her name. , That’s thanks to her completion of two ... Certified Professional Compliance Officer (CPCO.) , The CHC is designed to mitigate compliance-related ...
Breaking Medicine Technology: